This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
[Abstract:] A recently reported clinical trial yielded positive results for a CD73 inhibitor that reduces production of immunosuppressive adenosine in patients with pancreatic cancer. The patients, who also received chemotherapy and a PD-1 checkpoint inhibitor, had an overall response rate of 41%. Tumors shrank or stabilized in 85% of patients who received the drug for 16 weeks.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on February 12, 2021
doi: 10.1158/2159-8290.CD-NB2021-0313
Blocking CD73 Can Shrink Pancreatic Tumors
Jump to section
Advertisement